m i s s i o n
- Better transplantation technology
- Revival of gene-based therapy
- Faster, less invasive vaccination
March 5, 2010
The National Institute of Allergy and Infectious Diseases awarded Isogenis a grant for pre-clinical development of fully-deleted adenoviral gene therapy vectors for the treatment of hemophilia A and ornithine transcarbamylase deficiency. The grant is a two-year, Phase I SBIR. The research also makes use of Isogenis' veto technology to inhibit immune responses to the vectors themselves and to their therapeutic payload.
February 1, 2010
After the successful completion of its Phase I SBIR, Isogenis was awarded a Phase II SBIR grant to fund development of its proprietary CD8 veto technology for hepatocyte transplantation. This approach uses an ex-vivo gene therapy approach to overcome transplant rejection to treat both genetic disease and liver failure.
- "There are no such things as incurables;
- there are only things for which man has not
- found a cure."
- Bernard M. Baruch
Our proprietary vector-based technology surpasses the limitations of previous gene therapy vectors, avoiding dangerous immune reactions while delivering genetic therapies, bolstering immune preparedness against viral antigens, and potentially offering a streamlined vector platform for developers everywhere.
